A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.

OXXON Pharma AG0 个研究点目标入组 75 人开始时间: 2012年1月4日最近更新: 2014年2月3日

研究概览

暂无简介。

•1) Type 2 diabetes mellitus according to American Diabetes Association (ADA) definition
•2) Age = 18
•3) HbA1c between 6.0% and 10.5%, inclusive
•4) ACR > 100 mg/g calculated 3 times in first morning void urine, at least 2 of the measurements > 100 mg/g
•5) Patients on stable (unchanged medication for at least 3 months) treatment to control hypertension, hyperglycemia and (if applicable) dyslipidemia
•6) Stable treatment with angiotensin-converting enzyme inhibitors (ACEi) and/or Angiotensin II receptor blockers (ARBs) (renin-angiotensin system [RAS] blockade)
•7) Willing and able to understand and sign an approved Informed Consent form
•8) Men must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment. Women must be of non-childbearing potential
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 25

•1) Type 1 diabetes mellitus
•2) eGFR =25 mL/min/1.73m2 (calculated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula)
•3) Recent cardiovascular events (3 months)
•4) Uncontrolled hypertension (upper limits 180/110 mmHg)
•5) Dialysis and/or acute kidney injury within 3 months before screening
•6) Significant edema, infectious diseases, leg ulcers
•7) Severe concurrent disease which, in the judgment of the investigator, would interfere significantly with the assessments of safety and efficacy during this study
•8) Treatment with any other investigational agent, or participation in another clinical study within 90 days prior to baseline visit
•9) Patient with known infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
•10) In the judgment of the clinical investigator, clinically significant abnormal
•laboratory values at the screening visit
•11) Use of thiazolidinedione class drugs, immune suppressants, steroid therapy (except for topical use or inhalation), chronic use of non-steroidal anti-inflammatory drug (NSAIDs), cyclooxygenase type 2 (COX-2) inhibitors, two or more diuretic drugs and/or aliskiren
•12) In the judgment of the clinical investigator, patients who are likely to be non-
•compliant or uncooperative during the study
•13) Previous participation (randomization) in this study

发起方

OXXON Pharma AG